Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05055258 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II
A Phase 2 study, sponsored by KalVista Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT05055258 is a Phase 2 study that was terminated before completion, run by KalVista Pharmaceuticals. The registered enrollment target is 33 participants.
The verdict
NCT05055258, a Phase 2 study, was terminated before completion, sponsored by KalVista Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.
Interventions
- DRUG KVD824
- DRUG Placebo to KVD824
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2022-10-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05055258
The ClinicalTrials.gov registry entry for NCT05055258 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is KalVista Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which KVD824 is the first listed.
NCT05055258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05055258 about?
NCT05055258 is a clinical study titled "A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II". A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.
What is the current status of trial NCT05055258?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2021-11-18. Estimated completion is 2022-10-27.
What interventions are being tested in trial NCT05055258?
The interventions under investigation include: KVD824 (DRUG), Placebo to KVD824 (DRUG).
Who is sponsoring clinical trial NCT05055258?
This trial is sponsored by KalVista Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.